Clinical Trial Update: Dose Response to Recombinant Factor VIIa When Administered for Bleed [Phase 1]

View source ↗

Summary

Phase 1 study assessing the dose-response and safety of recombinant factor VIIa in individuals with congenital bleeding disorders (with healthy volunteers also …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bleeding Disorders

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Healthy | Phase 1 | Status: COMPLETED